# A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.

> **NCT00475423** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 122 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura

## Interventions

- **DRUG:** rituximab [MabThera/Rituxan]

## Key facts

- **NCT ID:** NCT00475423
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2015-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00475423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00475423, "A Study of MabThera (Rituximab) in Patients With Idiopathic Thrombocytopenic Purpura.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00475423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*